Tuesday, May 23, 2017 4:30:38 PM
They just got marketing approval yesterday. They're about to start operations very soon. Go ahead and buy the stock in a few weeks after they've started selling. It doesn't bother me. I'm going to continue to hold on to my shares (and I bought more today).
"They're diluting heavily"
This is not true. There is some dilution left, yes. But it's nothing out of the ordinary. The most recent q-10 looks just fine to me in terms of the notes payable section. Looks a lot better than the notes payable section in the 10-k. You need to have dilution in a pre revenue biotech. Period. How can the company fund operations BEFORE revenues kick in WITHOUT dilution? Can you explain that please? It's simply impossible as you know. Once revenues start, dilution will be a thing of the past.
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM